Dr Reddy's Labs (500124) Stock Analysis

The acquired NRT portfolio generated double-digit growth in Europe, exceeding the upper-single-digit steady-state aspiration. (3 exceeded, 2 met across 5 tracked commitments)

R&D expenditure remained within the guided 7%-8% range in Q4FY26. (4 met, 1 revised across 5 tracked commitments)

Ex-US branded and emerging-market businesses delivered double-digit growth in Q3FY26. Emerging Markets grew 32% year on year and India grew 19%; management reaffirmed that healthy double-digit Russia growth is sustainable and said all markets other than the United States should grow double digits. (1 exceeded, 1 met, 1 revised across 3 tracked commitments)

North America launch momentum continued in Q3FY26, with six new products added despite a 16% year-on-year revenue decline caused primarily by lower Lenalidomide sales and price erosion. (3 met, 2 in progress across 5 tracked commitments)

Management stated that North America base-business growth was double digit in Q1FY27 and reaffirmed double-digit growth for the full year, excluding lenalidomide and semaglutide. (1 met, 1 revised across 2 tracked commitments)

The scale moat expanded through a broad launch and filing program: seven North American launches, eight European launches, 24 Emerging Market launches and 43 global generic filings in Q2 FY26. The later baseline shows an even broader footprint, including 48 Emerging Market countries, 21 European countries, six North American launches, 43 Emerging Market launches and 24 European launches. This indicates continued geographic reach and product-launch scale. (4 expanding)

The company’s scale moat strengthened through breadth of launches, markets and regulatory filings. It operated in 48 emerging-market countries and 20 European countries, launched 24 products in Emerging Markets and 8 in Europe during the quarter, and had 73 pending ANDAs including 46 Para IV filings and 20 first-to-file opportunities. This increases future revenue visibility and supports the later baseline assessment of a strong scale advantage. (2 expanding)

India continued to expand. Revenue was Rs. 1,603 Cr in Q3 FY26, up 19% year over year, with more than 17% organic growth excluding the Stugeron acquisition. By Q1 FY27, India contributed 21% of company revenue and grew 17% year over year. Growth moderated slightly from 19% to 17%, but remained strong and above the domestic market, so the latest state is still expansion. (1 expanding)

Emerging Markets expanded, with revenue increasing 14% year over year and 18% sequentially to ₹1,655 Cr. Russia remained the largest contributor at 53% of the region, while the company launched 24 products and filed 32 new products in the quarter. The later baseline confirms stronger momentum, with the region reaching 23% of total revenue and 31% year-over-year growth. (5 expanding)

Global Generics remained the dominant business, accounting for 89% of revenue in Q2 FY26. Revenue grew 10% year over year to ₹7,850 Cr and 4% sequentially. This is an expanding revenue engine, although the later baseline shows that reported revenue subsequently declined 5% year over year in Q1 FY27 because of lower lenalidomide sales. (5 expanding across 2 engines)

Peptide manufacturing capacity is being expanded across API production and finished-product filling. Current Semaglutide supply is supported by partners with capacity for 12 million pens, while two FTO-11 cartridge lines could theoretically support up to 50 million units after qualification. API investment has potential capacity of up to 800 kg and is intended to support Semaglutide, Liraglutide and more than 40 additional peptide programs. This is a new, expanding capacity platform, but much of the future capacity remains theoretical. (1 accelerating, 1 steady across 2 signals, 1 leading indicator)

The US product pipeline remains substantial, with 73 pending ANDAs, including 46 Para IV filings and 20 first-to-file filings as of September 2025. However, no prior-quarter count is provided in this document, so the pipeline's multi-quarter direction cannot be established. (5 new trend across 5 signals)

India growth strengthened modestly on a reported basis, rising from 17% YoY in the previously extracted period to 19% in Q3 FY26. Organic growth was above 17%, indicating that most of the increase was generated internally rather than through acquisitions. Management described 15%-16% growth as sustainable and said organic growth was approximately 17%-18%, making the latest trend positive but not a clear acceleration beyond one quarter. (3 accelerating, 2 decelerating across 5 signals, 2 leading indicators)

Emerging Markets growth is strong and accelerating sequentially: revenue growth increased from 14% YoY to 18% QoQ in Q2 FY26, while revenue rose from Rs. 1,455 Cr in Q2 FY25 to Rs. 1,655 Cr. Growth is supported by 50 product launches in H1 FY26 and 48 countries served. (4 accelerating, 1 decelerating across 5 signals, 2 leading indicators)

The main near-term growth constraints are semaglutide quality and supply issues, US lenalidomide sales decline, pricing pressure in several markets, higher solvent and freight costs, and regulatory observations at the Bachupally biologics facility. These risks could delay product launches or reduce profitability. — Product quality, pricing and regulatory headwinds: North America revenue down 35% YoY; Europe NRT revenue down 2% YoY

Profitability weakened compared with Q2 FY25. Gross margin fell from 59.6% to 54.7%, while EBITDA margin fell from 28.4% to 26.7%. SG&A increased from 28.7% to 30.0% of revenue. The deterioration was partly visible in PSAI, where gross margin dropped from 30% to 18% because of lower operating leverage and product mix changes. This indicates that margin pressure was already intensifying before the later semaglutide-related deterioration in the baseline. (5 intensifying, 4 high-severity)

Management acknowledged that several products had been discontinued after failing to obtain approval and that meaningful US launches had been limited outside lenalidomide. The pipeline contained about 100 products, including roughly 20 complex generics, but management said these products were hard to predict. Compared with the Jul 2026 baseline, the risk remained material because later commentary still identified R&D productivity problems and a lack of major launches. The available evidence supports a broadly unchanged high risk rather than a clear improvement. (1 stable, 1 high-severity)

Domestic pricing controls remain a potential margin constraint for scheduled medicines. The presentation does not quantify Dr. Reddy’s NLEM exposure, but any applicable ceiling-price revisions or limits on price increases could reduce domestic pricing flexibility. [REGULATORY]

Emerging-market growth is partly dependent on favourable currency movements and is already being reduced by price erosion. A reversal in exchange rates or further local competition could weaken reported growth. [MARGIN_COST] (+1 more risk)

The risk remained relevant but was not clearly worsening in the available Q2 FY26 data. R&D spending declined to ₹620 crore, or 7.0% of revenue, from ₹727 crore, or 9.1%, in Q2 FY25. At the same time, the company filed five new US ANDAs in the quarter and had 73 pending ANDAs, including 46 Para IV and 20 first-to-file applications. These filings provide mitigation and future optionality, but the document does not report launch success rates or returns from prior R&D, so the underlying productivity risk cannot be fully reassessed. (1 stable)